REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm

Core Points - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities between November 22, 2024, and July 21, 2025, of the September 22, 2025, lead plaintiff deadline in a securities class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm [3] Case Details - The lawsuit alleges that Replimune's defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5] - The claims suggest that the defendants overstated the trial's prospects, leading to investor damages when the true information was revealed [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4] - The Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]